科研之友
微信
新浪微博
Facebook
分享链接
摘要
Purpose: To determine the efficacy of topical application of infliximab [tumor necrosis factor-alpha (TNF-alpha) monoclonal antibody] for the treatment of corneal neovascularization in the rabbit model. %26lt;br%26gt;Methods: In 12 rabbits (24 eyes), the corneal stroma was sutured to induce corneal neovascularization. One week after suture, corneal neovascularization was confirmed and the subjects were divided into 4 groups of 3 rabbits. Sterilized balanced salt solution was applied in the control group, and the experimental groups were treated with infliximab eye drops of varying concentrations (1, 2, and 4 mg/mL) twice daily for a week. The area of corneal neovascularization was measured and analyzed in all groups on day 3 and day 7. On day 7, all eyes were extracted to compare the TNF-alpha messenger RNA concentration by reverse transcriptase-polymerase chain reaction, and the vascular endothelial growth factor activity of corneal neo-vascular tissue was observed by fluorescence immunostaining. %26lt;br%26gt;Result: On day 7, all 3 experimental groups (1, 2, and 4 mg/mL) had a significantly reduced area of corneal neovascularization compared with the control group (P = 0.043, 0.027, and 0.01, respectively) and significantly reduced TNF-alpha messenger RNA (P = 0.038, 0.031, and 0.022, respectively). Fluorescence immunostaining confirmed the reduced expression of vascular endothelial growth factor in all 3 experimental groups compared with the control group. %26lt;br%26gt;Conclusions: The application of infliximab is expected to effectively inhibit corneal neovascularization. Further clinical studies are necessary.
- 出版日期2013-2
